This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Granules India has reported consolidated financial results for the period ended December 31, 2021
The investment will increase SpeeDx internal capacity to scale up manufacturing
The company has tied up with OrbiMed as a financial partner for global reach
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)